Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi’s Zimulti NDA Resubmission Could Be Late 2008, At Earliest

Executive Summary

Sanofi-Aventis will likely not be able to resubmit the NDA for its obesity drug Zimulti (rimonabant) until the end of 2008, at the earliest, when data becomes available from its ongoing study of the drug in diabetes patients

You may also be interested in...



Clouds Over CB Antagonists Cast Light On Rest Of Obesity Pipeline

With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile

Clouds Over CB Antagonists Cast Light On Rest Of Obesity Pipeline

With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile

Pharma Sales Growth: 2007 Starts High, But Expected To Taper By Year-End

BOSTON - Despite a strong start to 2007, growth in the pharmaceutical sector is expected to slow for the remainder of the year. According to IMS Health VP-Industry Relations Doug Long, "2007 has been a year that you could characterize as a fast start, slow finish.

Related Content

UsernamePublicRestriction

Register

PS048655

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel